Enfortumab vedotin-ejfv (solution)
Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate (ADC). Enfortumab vedotin-ejfv (solution) is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv (solution) is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma[1][2].
Product Specifications
CAS Number
1346452-25-2
UNSPSC
12352203
Target
Antibody-Drug Conjugates (ADCs) ; Nectin-4
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/enfortumab-vedotin-ejfv-solution.html
Purity
99.78
Solubility
10 mM in DMSO
Smiles
[Enfortumabvedotin-ejfv(solution)]
Molecular Weight
152000 (average)
References & Citations
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light
Scientific Category
ADC Related
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Recombinant SARS-CoV-2 Spike RBD (K417N, E484K, N501Y) (rFc Tag)
